TARO PHARMACEUTICAL INDUS (TARO) Stock Price, Forecast & Analysis
USA - NYSE:TARO - IL0010827181 - Common Stock
TARO Key Statistics, Chart & Performance
The current stock price of TARO is 42.97 USD. In the past month the price increased by 0.44%. In the past year, price increased by 10.83%.
TARO Latest News, Press Relases and Analysis
TARO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.64 | 991.57B | ||
| JNJ | JOHNSON & JOHNSON | 19.45 | 486.32B | ||
| MRK | MERCK & CO. INC. | 10.7 | 235.48B | ||
| PFE | PFIZER INC | 7.76 | 141.26B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.99 | 93.27B | ||
| ZTS | ZOETIS INC | 18.24 | 51.25B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.23 | 22.13B | ||
| VTRS | VIATRIS INC | 4.5 | 12.24B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.98 | 10.49B | ||
| CORT | CORCEPT THERAPEUTICS INC | 84.86 | 7.87B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.29B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.25B |
Related stock screener links
About TARO
Company Profile
Taro Pharmaceutical Industries Ltd. engages in the development, manufacturing and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada and Israel. The firm operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The firm markets over 200 pharmaceutical products in over 25 countries. The firm's owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The firm's other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.
Company Info
TARO PHARMACEUTICAL INDUS
14 Hakitor Street, PO Box 10347
Haifa 10532 IL
CEO: Uday Baldota
Employees: 1554
Phone: 97248475700
TARO PHARMACEUTICAL INDUS / TARO FAQ
What does TARO do?
Taro Pharmaceutical Industries Ltd. engages in the development, manufacturing and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada and Israel. The firm operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The firm markets over 200 pharmaceutical products in over 25 countries. The firm's owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The firm's other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.
Can you provide the latest stock price for TARO PHARMACEUTICAL INDUS?
The current stock price of TARO is 42.97 USD.
Does TARO PHARMACEUTICAL INDUS pay dividends?
TARO does not pay a dividend.
What is the ChartMill rating of TARO PHARMACEUTICAL INDUS stock?
TARO has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What do analysts say about TARO PHARMACEUTICAL INDUS (TARO) stock?
6 analysts have analysed TARO and the average price target is 43.86 USD. This implies a price increase of 2.07% is expected in the next year compared to the current price of 42.97.
Is TARO PHARMACEUTICAL INDUS (TARO) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TARO.
TARO Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to TARO. When comparing the yearly performance of all stocks, TARO turns out to be only a medium performer in the overall market: it outperformed 68.84% of all stocks.
TARO Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to TARO. While TARO has a great health rating, its profitability is only average at the moment.
TARO Financial Highlights
Over the last trailing twelve months TARO reported a non-GAAP Earnings per Share(EPS) of 1.72. The EPS increased by 156.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.55% | ||
| ROA | 2.49% | ||
| ROE | 3% | ||
| Debt/Equity | 0 |
TARO Forecast & Estimates
6 analysts have analysed TARO and the average price target is 43.86 USD. This implies a price increase of 2.07% is expected in the next year compared to the current price of 42.97.